Skip to main content
Livermore
Livermore
ZHEN

Qube Research & Technologies Ltd

SEC CIK
0001729829
Latest filing
Aug 14, 2026

HALO holding history

Halozyme Therapeutics, Inc. in every 13F filed by Qube Research & Technologies Ltd, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

HALO overviewAll 13F holders of HALOFull Q2 2026 holdings

Shares (Q1 2026)
0
Sold out in Q1 2026
Value
$0
% of portfolio
0.0%
Quarters held
16
Since Q1 2021
Holdings of HALO by Qube Research & Technologies Ltd, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q1 20260$00.0%−412,421−100.0%Sold outHolders
Q4 2025412,421$27.8M<0.1%−188,855−31.4%ReducedHolders
Q3 2025601,276$44.1M0.1%−384,793−39.0%ReducedHolders
Q2 2025986,069$51.3M0.1%+986,069NewHolders
Q1 20250$00.0%−245,750−100.0%Sold outHolders
Q4 2024245,750$11.7M<0.1%+17,644+7.7%AddedHolders
Q3 2024228,106$13.1M<0.1%+187,234+458.1%AddedHolders
Q2 202440,872$2.14M<0.1%−322,467−88.8%ReducedHolders
Q1 2024363,339$14.8M<0.1%+108,026+42.3%AddedHolders
Q4 2023255,313$9.44M<0.1%+229,532+890.3%AddedHolders
Q3 202325,781$984.8K<0.1%−112,574−81.4%ReducedHolders
Q2 2023138,355$4.99M<0.1%+119,311+626.5%AddedHolders
Q1 202319,044$727.3K<0.1%−85,672−81.8%ReducedHolders
Q4 2022104,716$5.96M<0.1%+104,716NewHolders
Q3 20220$00.0%−53,329−100.0%Sold outHolders
Q2 202253,329$2.35M<0.1%+53,329NewHolders
Q4 20210$00.0%−10,153−100.0%Sold outHolders
Q3 202110,153$413.0K<0.1%−11,579−53.3%ReducedHolders
Q2 202121,732$987.0K<0.1%−28,322−56.6%ReducedHolders
Q1 202150,054$2.09M<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.